Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2011, Article ID 904878, 9 pages
Research Article

Androidal Fat Dominates in Predicting Cardiometabolic Risk in Postmenopausal Women

1School of Health, Physical Education and Leisure Services, 133 Wellness/Recreation Center, University of Northern Iowa, Cedar Falls, IA 50614-0241, USA
2Food Science and Human Nutrition, Human Nutritional Sciences Building, Iowa State University, Ames, IA 50011-1123, USA
3Department of Statistics, 2413 Snedecor/2624C Howe, Iowa State University, Ames, IA 50011, USA
4Western Human Nutrition Research Center, University of California, Davis, CA 95616, USA

Received 14 September 2010; Revised 4 November 2010; Accepted 24 November 2010

Academic Editor: Christina Chrysohoou

Copyright © 2011 O. A. Matvienko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We hypothesized that soy isoflavones would attenuate the anticipated increase in androidal fat mass in postmenopausal women during the 36-month treatment, and thereby favorably modify the circulating cardiometabolic risk factors: triacylglycerol, LDL-C, HDL-C, glucose, insulin, uric acid, C-reactive protein, fibrinogen, and homocysteine. We collected data on 224 healthy postmenopausal women at risk for osteoporosis (45.8–65 y, median BMI 24.5) who consumed placebo or soy isoflavones (80 or 120 mg/d) for 36 months and used longitudinal analysis to examine the contribution of isoflavone treatment, androidal fat mass, other biologic factors, and dietary quality to cardiometabolic outcomes. Except for homocysteine, each cardiometabolic outcome model was significant (overall 𝑃 -values from ≤.0001 to .0028). Androidal fat mass was typically the strongest covariate in each model. Isoflavone treatment did not influence any of the outcomes. Thus, androidal fat mass, but not isoflavonetreatment, is likely to alter the cardiometabolic profile in healthy postmenopausal women.